PrescriptionGiant is a FREE prescription savings program that can save you up to 75% on your prescriptions with or without insurance!

Naxitamab-gqgk Injection

Actual product appearance may differ slightly.

Click the CARD below to print or take a screenshot on your mobile phone or tablet. There is no need to download another app!

If you would like to personalize your card enter your full name in the member name field below the card at this link and click the Update button.


Naxitamab-gqgk (brand name: Danyelza) is an FDA-approved medication used to treat relapsed or refractory high-risk neuroblastoma in pediatric patients. Like any medical treatment, Naxitamab-gqgk injection comes with potential risks and side effects. It’s essential to consult with a healthcare professional to understand the individual risks and benefits for a specific patient. Here are some common risks associated with Naxitamab-gqgk:

  • Infusion reactions: Some patients may experience infusion-related reactions during or shortly after receiving the injection. These reactions can include fever, chills, rash, itching, difficulty breathing, and changes in blood pressure. Healthcare providers closely monitor patients during the infusion to manage any adverse reactions that may occur.
  • Neurological events: Naxitamab-gqgk may cause neurological side effects, such as severe pain, headache, confusion, and seizures. These symptoms should be reported immediately to a healthcare professional.
  • Bone marrow suppression: This medication can lead to a decrease in certain blood cell counts, including red blood cells, white blood cells, and platelets. This may increase the risk of anemia, infections, and bleeding. Regular blood tests are necessary to monitor these levels.
  • Increased susceptibility to infections: Due to bone marrow suppression, patients taking Naxitamab-gqgk may become more susceptible to infections. It’s essential to report any signs of infection to a healthcare provider promptly.
  • Hypersensitivity reactions: Some individuals may experience allergic reactions to Naxitamab-gqgk, which can manifest as itching, hives, swelling, or severe anaphylaxis. In case of an allergic reaction, immediate medical attention is required.
  • Liver toxicity: Naxitamab-gqgk may cause liver damage, leading to abnormal liver function tests. Regular liver function monitoring is necessary during treatment.
  • Eye problems: Some patients may experience blurred vision or other eye-related issues while on this medication.
  • Secondary malignancies: There is a potential risk of developing secondary cancers as a result of treatment with Naxitamab-gqgk.

It’s crucial for patients and their caregivers to be aware of these potential risks and promptly report any concerning symptoms to their healthcare provider. Each patient’s medical history and individual condition will be assessed before treatment initiation to ensure that the potential benefits outweigh the risks. Always follow the prescribed treatment plan and attend regular check-ups to monitor for any adverse effects.

Why is this medication prescribed?

Naxitamab-gqgk (brand name: Danyelza) is prescribed to treat pediatric patients with relapsed or refractory high-risk neuroblastoma. Neuroblastoma is a rare type of cancer that develops from immature nerve cells and mostly affects children. “Relapsed” refers to the return of the cancer after initial treatment, and “refractory” means the cancer did not respond to previous treatments.

Naxitamab-gqgk is a type of immunotherapy known as a monoclonal antibody. It works by targeting a specific protein called GD2, which is present on the surface of neuroblastoma cells. By binding to this protein, Naxitamab-gqgk activates the body’s immune system, leading to the destruction of cancer cells and potentially slowing down the progression of the disease.

How should this medicine be used?

Naxitamab-gqgk is administered as an intravenous (IV) infusion, which means it is delivered directly into the bloodstream through a vein. The injection is typically given in a hospital or clinical setting by healthcare professionals who are experienced in administering such treatments.

The dosage and treatment schedule may vary based on the patient’s age, weight, overall health, and the severity of the neuroblastoma. Treatment cycles are usually repeated every few weeks, and the total duration of treatment will be determined by the patient’s response to the medication and the medical team’s assessment.

As with any medication, it is crucial to follow the healthcare provider’s instructions precisely. Patients and caregivers should inform the medical team about any other medications, supplements, or health conditions the patient may have to avoid potential drug interactions or complications.

Additionally, since Naxitamab-gqgk can cause infusion reactions, patients are closely monitored during and after each administration to manage any adverse effects that may occur. It’s essential to report any new or concerning symptoms to the healthcare provider promptly.

Always seek guidance from a pediatric oncologist or healthcare professional for personalized treatment recommendations and to address any questions or concerns regarding Naxitamab-gqgk injection and its usage.

Other uses for this medicine

Naxitamab-gqgk (Danyelza) was specifically approved for use in pediatric patients with relapsed or refractory high-risk neuroblastoma. It is not approved for other uses at that time. Naxitamab-gqgk is a monoclonal antibody that targets GD2 (disialoganglioside) expressed on neuroblastoma cells, and its approval was based on clinical trials demonstrating its efficacy in treating this specific type of cancer.

What special precautions should I follow?

Regarding special precautions for Naxitamab-gqgk injection, it’s essential to consider the following:

  • Pediatric Use: Naxitamab-gqgk is approved for use in pediatric patients, specifically those with high-risk neuroblastoma. The safety and efficacy in other age groups have not been established.
  • Infusion Reactions: Like many monoclonal antibody treatments, Naxitamab-gqgk may cause infusion-related reactions, such as fever, chills, itching, rash, or difficulty breathing. Healthcare providers typically administer premedications to reduce the risk of these reactions. Patients are closely monitored during the infusion and for a period afterward.
  • Immune System Suppression: Naxitamab-gqgk can weaken the immune system, which may increase the risk of infections. Patients should be monitored for signs of infections, and healthcare providers may recommend prophylactic antibiotics or other preventive measures.
  • Liver Function Monitoring: The medication may affect liver enzymes, so regular monitoring of liver function is usually performed during treatment.
  • Allergic Reactions: Severe allergic reactions, though rare, can occur with Naxitamab-gqgk. Patients should be monitored for any signs of allergic reactions during treatment.
  • Pregnancy and Breastfeeding: Naxitamab-gqgk may harm the fetus if administered during pregnancy, and its use during pregnancy is not recommended. It is essential to use effective contraception during treatment and for some time after the last dose. The use of Naxitamab-gqgk during breastfeeding is also not recommended.
  • Interactions with Other Medications: Patients should inform their healthcare providers about all medications, supplements, or herbal products they are taking before starting Naxitamab-gqgk treatment, as there may be potential interactions.

It’s essential to consult with a healthcare professional or refer to the most recent prescribing information for the most up-to-date and accurate information on the specific precautions and uses of Naxitamab-gqgk.

What special dietary instructions should I follow?

In general, a well-balanced diet that includes a variety of nutrient-rich foods is essential for supporting the body’s immune system and overall health during cancer treatment. If you have specific dietary concerns or restrictions, it’s best to discuss them with your healthcare provider or a registered dietitian who can provide personalized guidance.

What should I do if I forget a dose?

Regarding missed doses of Naxitamab-gqgk, it’s crucial to follow the recommendations of your healthcare provider. If you forget a scheduled dose, contact your healthcare team immediately for guidance. They will provide instructions on what to do next, which may include rescheduling the dose or adjusting the treatment plan as necessary.

What side effects can this medication cause?

Naxitamab-gqgk (trade name: Danyelza) is a monoclonal antibody used in the treatment of pediatric patients with high-risk neuroblastoma, a type of cancer. Like all medications, Naxitamab-gqgk can have potential side effects. It’s important to remember that individual responses to medications can vary, and not everyone will experience the same side effects. Some common side effects of Naxitamab-gqgk injection may include:

  • Infusion-related reactions: These can include fever, chills, nausea, vomiting, itching, rash, or difficulty breathing during or shortly after the infusion.
  • Pain: Patients may experience pain in the abdomen, extremities, or other areas of the body.
  • Fatigue: Feeling tired or weak is a possible side effect.
  • Headache: Some patients may experience headaches during treatment.
  • Infections: Naxitamab-gqgk can weaken the immune system, increasing the risk of infections.
  • Decreased blood cell counts: This medication can reduce the levels of white blood cells, red blood cells, and platelets in the blood, which may lead to an increased risk of infections, anemia, or bleeding.
  • Hypotension: Some patients may experience low blood pressure, leading to symptoms like dizziness or lightheadedness.
  • Elevated liver enzymes: It may cause an increase in certain liver enzymes, which is usually monitored during treatment.
  • Allergic reactions: In rare cases, severe allergic reactions may occur, which can cause difficulty breathing, swelling of the face, lips, tongue, or throat, and hives.

It’s essential for patients receiving Naxitamab-gqgk or any other medications to be closely monitored by their healthcare team. If you or someone you know is undergoing this treatment and experiences any concerning side effects, it’s important to contact the healthcare provider immediately.

What should I know about storage and disposal of this medication?

  • Storage: Naxitamab-gqgk injection should be stored according to the manufacturer’s instructions and the healthcare provider’s recommendations. Generally, it is kept refrigerated at a temperature between 2°C to 8°C (36°F to 46°F) until it is ready for use. Do not freeze the medication. Protect it from light and keep it in its original packaging until the time of administration.
  • Disposal: Unused or expired Naxitamab-gqgk should be disposed of properly following local regulations and guidelines for the disposal of medical waste. Do not dispose of medications in household trash or flush them down the toilet unless specifically instructed to do so. Check with your healthcare provider or pharmacist on the correct method of disposal.

In case of emergency/overdose

In the event of an emergency or potential overdose, seek immediate medical attention or contact your local poison control center. If possible, bring the medication’s container or packaging with you to the healthcare facility to assist medical professionals in providing appropriate care.

What other information should I know?

  • Regular Monitoring: During the course of Naxitamab-gqgk treatment, regular monitoring and follow-up visits with the healthcare provider are essential. This allows the medical team to assess the patient’s response to the treatment, manage side effects, and adjust the treatment plan as necessary.
  • Medical History: Before starting Naxitamab-gqgk treatment, inform the healthcare provider about any existing medical conditions, allergies, or medications the patient is currently taking. This includes prescription drugs, over-the-counter medications, vitamins, supplements, and herbal products.
  • Pregnancy and Breastfeeding: If a patient is pregnant or breastfeeding, it is essential to discuss the risks and benefits of Naxitamab-gqgk treatment with the healthcare provider. The potential risks to the developing fetus or newborn must be carefully considered.
  • Immunizations: During Naxitamab-gqgk treatment, patients should avoid live vaccines and discuss any immunization plans with the healthcare provider.
  • Follow Instructions: Always follow the healthcare provider’s instructions for administering the medication, attending appointments, and managing any side effects.
  • Supportive Care: The patient’s healthcare team may recommend additional supportive care measures to manage side effects and improve overall well-being during treatment.

Remember, Naxitamab-gqgk treatment is specific to each individual, and the healthcare provider will provide personalized guidance based on the patient’s unique medical situation. Open communication with the medical team is vital for a successful treatment journey.

Copyright © 2023